ストックスクリーナーアプリを入手
46.38
3.87%
1.73
前日終値:
$44.65
開ける：
$45.17
24時間の取引高:
272.95K
Relative Volume:
0.63
時価総額：
$2.20B
収益：
$379.25M
当期純損益:
$-77.34M
株価収益率:
-28.77
EPS:
-1.6122
ネットキャッシュフロー:
$-27.87M
1週間 パフォーマンス:
+4.32%
1か月 パフォーマンス:
+13.12%
6か月 パフォーマンス:
+3.83%
1年 パフォーマンス:
+85.82%
1日の値動き範囲:
$45.17
$46.57
1週間の範囲:
$43.50
$46.57
52週間の値動き範囲:
$24.07
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
46.38 | 2.20B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-19 | 再開されました | H.C. Wainwright | Buy |
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance
Insider Sell: Saira Ramasastry Sells 8,203 Shares of Mirum Pharm - GuruFocus
Mirum Pharmaceuticals director sells shares totaling $377,843 By Investing.com - Investing.com India
Mirum Pharmaceuticals director sells shares totaling $377,843 - Investing.com
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Alagille Syndrome Treatment Market Detailed in New Research ReportMirum Pharmaceuticals, Albireo Pharma - openPR.com
Two Sigma Investments LP Has $5.23 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Man Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential - Investing.com Nigeria
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
When the Price of (MIRM) Talks, People Listen - news.stocktradersdaily.com
Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes - Defense World
What is HC Wainwright’s Estimate for MIRM Q2 Earnings? - Defense World
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - citybiz
Comerica Bank Reduces Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Given “Buy” Rating at HC Wainwright - Defense World
Mirum Pharmaceuticals Names Doug Sheehy New Chief Legal Officer - Bloomberg Law News
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwri - GuruFocus
Mirum Pharmaceuticals (MIRM) Appoints New Chief Legal Officer | - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwright & Co. | MIRM Stock News - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating with Promising Growth Potential | MIRM Stock News - GuruFocus
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $60.64 - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - MSN
Northern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
FY2025 EPS Estimates for MIRM Raised by Cantor Fitzgerald - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for MIRM - Defense World
JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $76.00 - Defense World
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JMP raises Mirum Pharmaceuticals stock target to $76 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Nigeria
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
Mirum Pharmaceuticals Inc (MIRM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ramasastry Saira | Director |
Jun 02 '25 |
Sale |
46.20 |
5,703 |
263,492 |
0 |
| Ramasastry Saira | Director |
Jun 03 '25 |
Sale |
45.74 |
2,500 |
114,352 |
0 |
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):